 |
|
New Techniques for Imaging Human Immunodeficiency Virus–Associated Cognitive Impairment in the Era of Highly Active Antiretroviral Therapy
Martin G. Pomper, MD, PhD;
Ned Sacktor, MD
Arch Neurol. 2007;64(9):1233-1235.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Human immunodeficiency virus 1 (HIV-1)–associated dementia complex (HIV dementia) occurs in 10% to 15% of HIV-seropositive individuals with advanced infection and is characterized by cognitive, behavioral, and motor dysfunction. The clinical phenotype of HIV dementia has changed as a result of highly active antiretroviral therapy (HAART) so that mild forms of HIV-associated cognitive impairment predominate, and there is evidence of lower cerebrospinal fluid (CSF) HIV RNA levels and less central nervous system (CNS) immune activation.1 Many surrogate markers from the pre-HAART era are no longer associated with HIV dementia, suggesting an attenuated CNS inflammatory response in HIV-positive individuals receiving HAART. There is an urgent need to identify new surrogate laboratory and neuroimaging markers of HIV-associated cognitive impairment in the era of HAART.
Neuroimaging studies of HIV infection are used principally to exclude CNS opportunistic processes. Magnetic resonance imaging (MRI) can also demonstrate . . . [Full Text of this Article] AUTHOR INFORMATION
RELATED ARTICLE
Detection of Human Immunodeficiency Virus–Induced Inflammation and Oxidative Stress in Lenticular Nuclei With Magnetic Resonance Spectroscopy Despite Antiretroviral Therapy
Anne C. Roc, Beau M. Ances, Sanjeev Chawla, Marc Korczykowski, Ronald L. Wolf, Dennis L. Kolson, John A. Detre, and Harish Poptani
Arch Neurol. 2007;64(9):1249-1257.
ABSTRACT
| FULL TEXT
|
